Conditions: Friedreich Ataxia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 22
Healthy volunteers: no

Brief summary:
The purpose of this protocol is to determine the efficacy of EGb 761 120 mg bid versus placebo in patients suffering from Friedreich Ataxia

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: EGb 761 120 mg intervention 2: Placebo
Intervention descriptions: intervention 1: EGb 761® 120 mg bid, orally for 12 to 14 weeks intervention 2: Placebo 1 tablet BID, orally for 12 to 14 weeks

Protocol document: